UA123212U - Спосіб лікування раку молочної залози - Google Patents

Спосіб лікування раку молочної залози

Info

Publication number
UA123212U
UA123212U UAA201213781U UAA201213781U UA123212U UA 123212 U UA123212 U UA 123212U UA A201213781 U UAA201213781 U UA A201213781U UA A201213781 U UAA201213781 U UA A201213781U UA 123212 U UA123212 U UA 123212U
Authority
UA
Ukraine
Prior art keywords
treatment
methods
breast cancer
entinostat
resistant
Prior art date
Application number
UAA201213781U
Other languages
English (en)
Ukrainian (uk)
Inventor
Робєрт Гуденау
Пітер Ордентліх
Original Assignee
Общєство С Огранічєной Отвєтствєностью "Новамедіка"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47756940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA123212(U) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Общєство С Огранічєной Отвєтствєностью "Новамедіка" filed Critical Общєство С Огранічєной Отвєтствєностью "Новамедіка"
Priority to UAU201711134U priority Critical patent/UA124239U/uk
Priority to UAU201711136U priority patent/UA124241U/uk
Priority to UAU201711135U priority patent/UA124240U/uk
Priority to UAU201711132U priority patent/UA124238U/uk
Publication of UA123212U publication Critical patent/UA123212U/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/4833Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
UAA201213781U 2011-09-02 2012-08-31 Спосіб лікування раку молочної залози UA123212U (uk)

Priority Applications (4)

Application Number Priority Date Filing Date Title
UAU201711134U UA124239U (uk) 2011-09-02 2012-08-31 Спосіб лікування раку молочної залози
UAU201711136U UA124241U (uk) 2011-09-02 2012-08-31 Спосіб вибору пацієнта для подальшої терапії er-позитивного раку молочної залози
UAU201711135U UA124240U (uk) 2011-09-02 2012-08-31 Спосіб вибору пацієнта для подальшої терапії er-позитивного раку молочної залози
UAU201711132U UA124238U (uk) 2011-09-02 2012-08-31 Спосіб лікування раку молочної залози

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161530873P 2011-09-02 2011-09-02
US201161532534P 2011-09-08 2011-09-08
US201161628999P 2011-11-12 2011-11-12
US201161568110P 2011-12-07 2011-12-07
PCT/US2012/053551 WO2013033656A1 (en) 2011-09-02 2012-08-31 Methods for the treatment of breast cancer

Publications (1)

Publication Number Publication Date
UA123212U true UA123212U (uk) 2018-02-26

Family

ID=47756940

Family Applications (6)

Application Number Title Priority Date Filing Date
UAA201213781U UA123212U (uk) 2011-09-02 2012-08-31 Спосіб лікування раку молочної залози
UAU201711135U UA124240U (uk) 2011-09-02 2012-08-31 Спосіб вибору пацієнта для подальшої терапії er-позитивного раку молочної залози
UAU201711136U UA124241U (uk) 2011-09-02 2012-08-31 Спосіб вибору пацієнта для подальшої терапії er-позитивного раку молочної залози
UAU201711132U UA124238U (uk) 2011-09-02 2012-08-31 Спосіб лікування раку молочної залози
UAA201512370U UA149007U (uk) 2011-09-02 2012-08-31 Спосіб лікування er-позитивного раку молочної залози
UAU201711134U UA124239U (uk) 2011-09-02 2012-08-31 Спосіб лікування раку молочної залози

Family Applications After (5)

Application Number Title Priority Date Filing Date
UAU201711135U UA124240U (uk) 2011-09-02 2012-08-31 Спосіб вибору пацієнта для подальшої терапії er-позитивного раку молочної залози
UAU201711136U UA124241U (uk) 2011-09-02 2012-08-31 Спосіб вибору пацієнта для подальшої терапії er-позитивного раку молочної залози
UAU201711132U UA124238U (uk) 2011-09-02 2012-08-31 Спосіб лікування раку молочної залози
UAA201512370U UA149007U (uk) 2011-09-02 2012-08-31 Спосіб лікування er-позитивного раку молочної залози
UAU201711134U UA124239U (uk) 2011-09-02 2012-08-31 Спосіб лікування раку молочної залози

Country Status (15)

Country Link
US (2) US10226472B2 (https=)
EP (2) EP2751267B1 (https=)
JP (2) JP6195384B2 (https=)
KR (1) KR101956861B1 (https=)
CN (3) CN103906837A (https=)
AU (2) AU2012301616B2 (https=)
BR (1) BR112014005080A2 (https=)
CA (1) CA2847348A1 (https=)
EA (1) EA201201474A1 (https=)
ES (1) ES2663407T3 (https=)
GE (1) GEP201706612B (https=)
HK (1) HK1254859A1 (https=)
MX (1) MX358254B (https=)
UA (6) UA123212U (https=)
WO (1) WO2013033656A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103906837A (zh) 2011-09-02 2014-07-02 辛达克斯制药股份有限公司 治疗乳腺癌的方法
CN105492007A (zh) * 2013-05-03 2016-04-13 欣达克斯制药公司 癌症治疗方法
WO2016145294A1 (en) * 2015-03-12 2016-09-15 The University Of Chicago Methods for determining prognosis for breast cancer patients
AU2016318136B2 (en) 2015-09-02 2022-10-20 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
GB2567093A (en) 2016-07-15 2019-04-03 Viracta Therapeutics Inc Histone deacetylase inhibitors for use in immunotherapy
EP3487492A4 (en) * 2016-07-20 2020-03-11 Eisai R&D Management Co., Ltd. USE OF ERIBULIN AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
AU2019266231B2 (en) 2018-05-07 2025-08-21 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
KR102212699B1 (ko) 2019-08-12 2021-02-05 한국원자력의학원 유방암 예방 또는 치료용 조성물
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US12251991B2 (en) 2020-08-20 2025-03-18 Denso International America, Inc. Humidity control for olfaction sensors
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US12377711B2 (en) 2020-08-20 2025-08-05 Denso International America, Inc. Vehicle feature control systems and methods based on smoking
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US12269315B2 (en) 2020-08-20 2025-04-08 Denso International America, Inc. Systems and methods for measuring and managing odor brought into rental vehicles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
WO2008021542A2 (en) 2006-08-17 2008-02-21 Cell Signaling Technology, Inc. Lysine acteylation sites
EP2167090A4 (en) * 2007-06-06 2010-08-25 Univ Maryland HDAC INHIBITORS AND HORMONE TREATMENT MEDICAMENTS
WO2008154382A1 (en) * 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2009067500A1 (en) 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac
RU2013140471A (ru) 2011-02-02 2015-03-10 Дженентек, Инк. Дозирование для лечения антителами против egfl7
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CN103906837A (zh) 2011-09-02 2014-07-02 辛达克斯制药股份有限公司 治疗乳腺癌的方法
CH706458B1 (fr) 2012-04-30 2017-05-15 Granit Tech Sa Procédé de cimentation pour le stockage de déchets.

Also Published As

Publication number Publication date
EP2751267A1 (en) 2014-07-09
KR20140108629A (ko) 2014-09-12
KR101956861B1 (ko) 2019-03-12
GEP201706612B (en) 2017-02-10
AU2018203059A1 (en) 2018-05-17
JP2017149761A (ja) 2017-08-31
US10226472B2 (en) 2019-03-12
MX358254B (es) 2018-08-10
UA124239U (uk) 2018-03-26
US20140378420A1 (en) 2014-12-25
HK1254859A1 (zh) 2019-07-26
WO2013033656A1 (en) 2013-03-07
ES2663407T3 (es) 2018-04-12
UA149007U (uk) 2021-10-13
JP2014525465A (ja) 2014-09-29
UA124238U (uk) 2018-03-26
EP3381454A1 (en) 2018-10-03
UA124240U (uk) 2018-03-26
EA201201474A1 (ru) 2013-08-30
AU2012301616A1 (en) 2014-04-17
CA2847348A1 (en) 2013-03-07
UA124241U (uk) 2018-03-26
JP6195384B2 (ja) 2017-09-13
US20190343844A1 (en) 2019-11-14
MX2014002515A (es) 2015-05-07
BR112014005080A2 (pt) 2017-03-28
AU2012301616B2 (en) 2018-02-08
CN107982270A (zh) 2018-05-04
EP2751267A4 (en) 2015-01-07
EP2751267B1 (en) 2018-01-24
CN103906837A (zh) 2014-07-02
CN114053284A (zh) 2022-02-18

Similar Documents

Publication Publication Date Title
UA123212U (uk) Спосіб лікування раку молочної залози
CA144351S (en) Sofa
CA143819S (en) Intravenous line organizer
CA146763S (en) Lighting
CA141065S (en) Dual c clip
AU333422S (en) Showerhead
CA143665S (en) Boot
UA117663C2 (uk) Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози
GB201608839D0 (en) Biomarkers useful for detectionof types, grades and stages of human breast cancer
MX2013003599A (es) Interferon-beta para uso como monoterapia o en combinacion con otras terapias de cancer.
CA144250S (en) Sofa
CA143988S (en) Knife sharpener
CA145279S (en) Loudspeaker
CA140176S (en) Door lever
PH12014502461A1 (en) Biomarkers for iap inhibitor therapy
CA143667S (en) Shoe
CA143657S (en) Sink
GB201113482D0 (en) Assay
MX350868B (es) Medicamentos y metodos para tratar cancer.
CA145280S (en) Loudspeaker
CA142814S (en) Medical patch
PH12012501547A1 (en) Methods of preparing thiazolidines
CA147931S (en) Peeler blade
CA144249S (en) Chair
CA144748S (en) Door stop